OSU as Network Lead Academic Participating Site for the NCI NCTN

OSU 作为 NCI NCTN 网络主导学术参与网站

• 批准号: 8605679
• 负责人: JOHN C. BYRD
• 金额: $ 145.58万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-05-06 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8605679
• 关键词: Address; Adult; Affect; Ally; American College of Radiology Imaging Network; Area; Basic Science; Biochemistry; Biological Markers; Biomedical Research; Biometry; CEBPA gene; Cancer Center; Cancer Hospital; Cancer Patient; Chronic Myeloid Leukemia; Clinic; Clinical; Clinical Research; Clinical Sciences; Clinical Trials; Clinical Trials Network; Comprehensive Cancer Center; Contracts; Cytotoxic agent; Data; Decitabine; Development; Discipline; Disease; Eastern Cooperative Oncology Group; Education; Enrollment; Epidemiologist; Faculty; Fostering; Funding; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Generations; Genetic; Goals; Grant; Gynecologic Oncology; Gynecologic Oncology Group; Health Personnel; Hematologic Neoplasms; Hematopoietic Neoplasms; Heterogeneity; Histology; Imatinib; Immunology; Individual; Inpatients; Knowledge; Laboratory Research; Laboratory Scientists; Lead; Leadership; Learning; Malignant Neoplasms; Measures; Medical; Medical Oncology; Minority; Modeling; Molecular Genetics; National Surgical Adjuvant Breast and Bowel Project; Nurses; Oblimersen; Ohio; Operative Surgical Procedures; Outcome; Outpatients; Pathologist; Patients; Peer Review; Pentostatin; Performance; Pharmacists; Pharmacodynamics; Pharmacology; Phase; Physicians; Postdoctoral Fellow; Protocols documentation; Psychiatrist; Quality of life; Radiation; Radiation Oncologist; Radiation Therapy Oncology Group; Radio; Rare Diseases; Research; Research Activity; Research Design; Research Infrastructure; Research Personnel; Resources; Risk; Science; Scientist; Site; Solid Neoplasm; Southwest Oncology Group; Structure; Surgical Oncologist; Surgical Oncology; Symptoms; TNFRSF5 gene; Testing; Therapeutic; Therapeutic Agents; Therapeutic Index; Tissues; Toxic effect; Training; Translating; Translational Research; Tumor Biology; Universities; base; bcr-abl Fusion Proteins; cancer prevention; career development; college; design; disorder subtype; doctoral student; improved; lenalidomide; leukemia; meetings; member; new technology; next generation; next generation sequencing; novel; novel therapeutics; phase 1 study; phase 3 study; pre-clinical; preclinical study; programs; public health relevance; research study; rituximab; sound; stem; success; treatment trial; tumor

DESCRIPTION (provided by applicant): Faculty from The Ohio State University (OSU) are integrated into the scientific and administrative activities, participate in meetings, manage multiple core labs, design studies and enroll patients in all existing adult NCTN network groups using cancer center resources to leverage group resources. OSU investigators develop and lead studies designed to enroll patients on multi-disciplinary treatment trials as well as develop and perform correlative science related research studies, bringing special expertise in hematologic malignancies and solid tumors. Our medical, hematologic, surgical and radiation oncologists, trans planters, psychiatrists, pathologists, cytogeneticists, translational and basic laboratory scientists, statisticians, epidemiologists, nurses, pharmacists, and clinical research coordinators help to frame the clinical and basic science questions whose answers contribute to improved patient outcomes and to understanding tumor biology. The goal of this application is to provide the infrastructure to support OSU's participation in the scientific and clinical research activities of the NCI's NCTN Program as a Network Lead Academic Participating Site (NLAPS). We will use the support to make scientific discoveries about tumor biology, find better treatments and augment the quality of life for patients thus improving outcomes across the spectrum of cancers affecting adults. This comprehensive program aims to: 1) Investigate new therapeutic agents, and their toxicities in Phase I to 1 clinical trials; 2) Evaluate the efficacy nd toxicity of novel combinations based on preclinical data to exploit synergistic combinations more effectively; 3) Develop multi-modal approaches using surgical, immunological, and radio therapeutic measures in optimal combinations; 4) Integrate experts in molecular genetics, biochemistry, pharmacology, immunology, and biostatistics in the design and execution of therapeutic protocols; 5) Improve cancer outcomes through discovery and education of pre and post-doctoral students, nurses, allied medical personnel and physicians, 6) Understand and exploit tumor heterogeneity to fully exploit the value of targeted therapies, 7) Improve the management of cancer related symptoms, and 8) enroll patients on trials.

描述（由申请人提供）：来自俄亥俄州立大学（OSU）的教师被整合到科学和行政活动中，参与会议，管理多个核心实验室，设计研究并使用癌症中心资源利用小组资源在所有现有的成人NCTN网络组中招募患者。俄勒冈州立大学的研究人员开发和领导研究，旨在招募患者进行多学科治疗试验，并开发和执行相关科学研究，带来血液恶性肿瘤和实体肿瘤的特殊专业知识。我们的内科、血液学、外科和放射肿瘤学家、移植医生、精神科医生、病理学家、细胞遗传学家、转化和基础实验室科学家、统计学家、流行病学家、护士、药剂师和临床研究协调员帮助构建临床和基础科学问题，这些问题的答案有助于改善患者的治疗效果和理解肿瘤生物学。该应用程序的目标是提供基础设施，以支持俄勒冈州立大学参与NCI的NCTN计划的科学和临床研究活动，作为网络领导学术参与站点（nlap）。我们将利用这笔资金在肿瘤生物学方面做出科学发现，找到更好的治疗方法，提高患者的生活质量，从而改善影响成人的各种癌症的预后。该综合项目旨在：1)在I - 1期临床试验中研究新的治疗药物及其毒性；2)基于临床前数据评估新组合的疗效和毒性，以更有效地开发协同组合；3)采用手术、免疫和放射治疗措施的最佳组合开发多模式方法；4)整合分子遗传学、生物化学、药理学、免疫学和生物统计学专家设计和执行治疗方案；5)通过对博士生、博士后、护士、相关医务人员和医生的发现和教育，改善癌症预后；6)了解和利用肿瘤异质性，充分发挥靶向治疗的价值；7)改善癌症相关症状的管理；8)招募患者进行试验。